Feb 17 (Reuters) - H Lundbeck A/S LUN.CO
* Health Canada approves Otsuka and Lundbeck's REXULTI(tm) (brexpiprazole) as a treatment for schizophrenia in adults
* Lundbeck Canada - REXULTI will be co-marketed by two companies and is expected to become commercially available in Canada this spring Source text: [ Further company coverage: LUN.CO